Feature Channels: Pharmaceuticals

• share
• favorite_border

Memorial Sloan Kettering Cancer Center (MSK) announced today that the U.S. Food and Drug Administration (FDA) has approved the oral MEK inhibitor drug cobimetinib (Cotellic®) for the treatment of adult patients with the family of blood diseases known as histiocytic neoplasms (HN). These diseases include Erdheim-Chester disease, Rosai-Dorfman disease, and Langerhans cell histiocytosis. Cobimetinib is an oral inhibitor of MEK1 and MEK2, currently approved to treat melanoma.

• share
• favorite_border

Binghamton University Assistant Professor of Chemistry Jennifer Hirschi recently received a Maximizing Investigators’ Research Award for $1.93 million from the National Institute of General Medical Sciences to study the mechanisms involved in catalytic reactions.

• share
• favorite_border

UC San Diego researchers and others report that more than one-third of the COVID-19 patients who did not receive any treatment experienced complete resolution of symptoms for at least two consecutive days, but then subsequently reported a return of symptoms.

• share
• favorite_border

A new study led by Duke Health found that advanced practice clinicians received more payments from drug companies, while physicians accepted more funds from medical device companies. The same proportion of each group accepted payments, but the physicians received a much greater sum.

• share
• favorite_border

To expand access to safe, high-quality anesthesia services to veterans, Rep. Lauren Underwood (IL-D) along with 12 Congressional colleagues requested that CRNAs be granted full practice authority permanently across VA facilities.

• share
• favorite_border

A drug approved to treat breast cancer patients with mutations in the BRCA1 or BRCA2 genes may also benefit people who have other genetic mutations.

• share
• favorite_border

A Ludwig Cancer Research study has developed a novel nanotechnology that triggers potent therapeutic anti-tumor immune responses and demonstrated its efficacy in mouse models of multiple cancers.

• share
• favorite_border

• share
• favorite_border

Researchers say hydroquinine could be an effective weapon against a germ that can cause serious infections in humans, mostly hospital patients.

• share
• favorite_border

A University of Kentucky Markey Cancer Center researcher’s team developed new chemical compounds that show promise as a potential anticancer therapy to treat aggressive tumors. The study led by Samuel G. Awuah, Ph.D., was published in Chemical Communications with Adedamola Arojojoye, a graduate student in Awuah’s lab as the paper’s first author.

• share
• favorite_border

New research from Yale Cancer Center reveals for the first time ever a differential clinical response to pembrolizumab in Lynch-like (mutated) vs methylated microsatellite instability-high (MSI-H) uterine cancer patients, increasing our understanding about the proportion of patients that derive benefit from immune checkpoint blockade.

• share
• favorite_border

Donald E. Arnold, M.D., FASA, was today elected as first vice president of the American Society of Anesthesiologists (ASA), the nation’s largest organization of physician anesthesiologists. Dr. Arnold was elected by the House of Delegates at the ANESTHESIOLOGY® 2022 annual meeting and will serve for one year.

• share
• favorite_border

The American Society of Anesthesiologists (ASA) today presented James D. Grant, M.D., MBA, FASA, with its 2021 Distinguished Service Award in recognition of his highly distinguished career as a physician anesthesiologist, enduring contributions to ASA members and deep commitment to advocating for the specialty and protecting patient safety.

• share
• favorite_border

American Society of Anesthesiologists names Michael W. Champeau, M.D., FASA, new president

• share
• favorite_border

Researchers at UC San Diego have identified a new signaling process involving G protein-coupled receptors (GPCRs), a cellular target already exploited by hundreds of diverse drugs. The discovery opens the possibility of new therapies, including for multiple forms of cancer.